MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase…
MaaT PharmaDecember 11, 2023
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical…
MaaT PharmaNovember 30, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaNovember 13, 2023
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results Independent Data Safety…
MaaT PharmaNovember 9, 2023
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in…
MaaT PharmaNovember 6, 2023
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference…
MaaT PharmaNovember 2, 2023
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed…
MaaT PharmaOctober 31, 2023
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial…
MaaT PharmaOctober 26, 2023
MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler…
MaaT PharmaOctober 9, 2023
